Spurious Drugs Alert: Diazepam, PAN 40, and PAN-D Capsules Under Investigation

The batches under scrutiny are Diazepam Injection I.P. (Batch No. DA-2403), Pantoprazole Gastro-resistant Tablets PAN 40 (Batch No. 24440993), and Pantoprazole Gastro-resistant and Domperidone Prolonged-Release Capsules PAN-D (Batch No. 23443507). These drugs, commonly used in hospitals and for outpatient treatment, were tested in CDSCO laboratories in Bihar in August 2025.

According to official reports, the products are under investigation. The manufacturers for these batches are currently under investigation.

In accordance with the Drug and Cosmetic Act, a drug shall be deemed to be spurious—

(a) if it is imported under a name which belongs to another drug; or

(b) if it is an imitation of, or a substitute for, another drug or resembles another drug in a manner likely to deceive or bears upon it or upon its label or container the name of another drug unless it is plainly and conspicuously marked so as to reveal its true character and its lack of identity with such other drug; or

(c) if the label or the container bears the name of an individual or company purporting to be the manufacturer of the drug, which individual or company is fictitious or does not exist; or

(d) if it has been substituted wholly or in part by another drug or substance; or

(e) if it purports to be the product of a manufacturer of whom it is not truly a product

The term “Spurious Drug” has been defined under Section 17-B of the Drugs and Cosmetics Act, 1940

Medicines Flagged as Spurious